Design Therapeutics, Inc.
DSGN
$4.75
$0.0250.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -15.28% | 17.42% | 40.85% | 42.44% | 31.71% |
| Total Depreciation and Amortization | 7.97% | 11.68% | 13.53% | 10.85% | 11.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 127.32% | 9.55% | -25.81% | -36.49% | -59.19% |
| Change in Net Operating Assets | 181.13% | 519.25% | -136.75% | -430.56% | -3,053.97% |
| Cash from Operations | 22.96% | 34.32% | 18.43% | 28.61% | 15.19% |
| Capital Expenditure | 100.00% | 130.19% | -80.90% | -124.14% | 90.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -67.18% | -138.14% | 127.77% | 5.00% | 826.82% |
| Cash from Investing | -67.02% | -138.16% | 128.12% | 4.47% | 626.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -47.50% | -92.31% | 9.05% | -- | 285.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -47.50% | -92.31% | 9.05% | -- | 285.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.17% | -2,163.22% | 1,111.29% | 255.00% | 57.91% |
